How to run clinical trials in the Middle East - introduction
This article was originally published in Scrip
Executive Summary
The attractions of the Middle East as a location for clinical research include patient diversity, world-class medical facilities, cost advantages and favourable infrastructure. Indeed multinational CROs think the region is about to experience a surge in clinical trials. Yet there are major discrepancies between countries in terms of adherence to regulations and political stability, reports Faraz Kermani.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.